A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

NCT06185673 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Oculopharyngeal Muscular Dystrophy

Interventions

GENETIC: BB-301: Dose escalation phase 1b cohort 1
GENETIC: BB-301: Dose escalation phase 1b cohort 2
GENETIC: BB-301: Dose escalation phase 1b cohort 3
GENETIC: BB-301: Dose expansion phase 2a

Sponsor

Benitec Biopharma, Inc.